These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 32524766)

  • 21. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Switching epoetin alfa and epoetin zeta in patients with renal anemia on dialysis: Posthoc analysis.
    Więcek A; Ahmed I; Scigalla P; Koytchev R
    Adv Ther; 2010 Dec; 27(12):941-52. PubMed ID: 20972656
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Results from a safety cohort of patients with renal anemia receiving the biosimilar epoetinzeta: The PASCO I study.
    Dellanna F; Fluck RJ; Lonnemann G; Wild CA; Iwanowitsch A; Meissner R; Audhya P
    Clin Nephrol; 2015 Nov; 84(5):280-8. PubMed ID: 26396097
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of hyporesponsiveness to erythropoietin-stimulating agents on time-dependent mortality risk among CKD stage 5D patients: a single-center cohort study.
    Ishigami J; Onishi T; Shikuma S; Akita W; Mori Y; Asai T; Kuwahara M; Sasaki S; Tsukamoto Y
    Clin Exp Nephrol; 2013 Feb; 17(1):106-14. PubMed ID: 22752396
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose conversion ratio one year after switching from epoetin alpha to darbepoetin alpha in Japanese hemodialysis patients.
    Hirai T; Nakashima A; Shiraki N; Takasugi N; Yorioka N
    Int J Artif Organs; 2010 May; 33(5):283-9. PubMed ID: 20593349
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biosimilar epoetin zeta in nephrology - a single-dialysis center experience.
    Lonnemann G; Wrenger E
    Clin Nephrol; 2011 Jan; 75(1):59-62. PubMed ID: 21176751
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Switching Between Epoetins: A Practice in Support of Biosimilar Use.
    D'Amore C; Da Cas R; Rossi M; Traversa G
    BioDrugs; 2016 Feb; 30(1):27-32. PubMed ID: 26728875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease.
    Weir MR; Pergola PE; Agarwal R; Fink JC; Kopyt NP; Singh AK; Kumar J; Schmitt S; Schaffar G; Rudy A; McKay JP; Kanceva R
    Am J Nephrol; 2017; 46(5):364-370. PubMed ID: 29084409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Opatija study: observation of hemodialysis patients and titration of CERA dose just switched from another erythropoiesis stimulating agent].
    Jelić I; Lovcić V; Kurtović I; Josipović M; Havranek Z; Kostić L; Racki S
    Acta Med Croatica; 2012 Jul; 66(3):157-64. PubMed ID: 23441529
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of biosimilar drugs in the treatment of renal anemia: A case series.
    Muñoz Ramos P; Gil Giraldo Y; Álvarez Chiva V; Quiroga B
    Medwave; 2021 Oct; 21(9):e8474. PubMed ID: 34669690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short-acting erythropoiesis-stimulating agents for anaemia in predialysis patients.
    Hahn D; Esezobor CI; Elserafy N; Webster AC; Hodson EM
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD011690. PubMed ID: 28066881
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Subcutaneous administration of darbepoetin alfa effectively maintains hemoglobin concentrations at extended dose intervals in peritoneal dialysis patients.
    Fang YW; Chang CH
    Perit Dial Int; 2009; 29(2):199-203. PubMed ID: 19293358
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia.
    Baldamus C; Krivoshiev S; Wolf-Pflugmann M; Siebert-Weigel M; Koytchev R; Bronn A
    Adv Ther; 2008 Nov; 25(11):1215-28. PubMed ID: 18931828
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship between responsiveness to erythropoiesis-stimulating agent and long-term outcomes in chronic hemodialysis patients: a single-center cohort study.
    Ogawa T; Shimizu H; Kyono A; Sato M; Yamashita T; Otsuka K; Nitta K
    Int Urol Nephrol; 2014 Jan; 46(1):151-9. PubMed ID: 23807369
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An induction dose of epoetin alpha of 40 000 IU daily for three consecutive days increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
    Mustacchi G; Ceccherini R; Dellach C; Foladore S; Milani S; Leita M; Sisto M
    Ann Oncol; 2006 Nov; 17(11):1705-8. PubMed ID: 16980603
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anemia Evaluation and Erythropoietin Dose Requirement Among Hemodialysis Patients: a Multicenter Study.
    Nafar M; Samavat S; Khoshdel A; Alipour-Abedi B
    Iran J Kidney Dis; 2017 Jan; 11(1):56-65. PubMed ID: 28174354
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Resistance index to epoetin alpha and to darbepoetin-alpha in chronic hemodialysis patients: a cohort study].
    Pérez-García R; Rodríguez Benítez P; Jofre R; López-Gómez JM; Villaverde MT; Blanco A; Blanco S; Sánchez M
    Nefrologia; 2007; 27(3):340-9. PubMed ID: 17725454
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin.
    Kapoian T; O'Mara NB; Singh AK; Moran J; Rizkala AR; Geronemus R; Kopelman RC; Dahl NV; Coyne DW
    J Am Soc Nephrol; 2008 Feb; 19(2):372-9. PubMed ID: 18216316
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospective multicenter study of HX575 (biosimilar epoetin-α) in patients with chronic kidney disease applying a target hemoglobin of 10--12 g/dl.
    Hörl WH; Locatelli F; Haag-Weber M; Ode M; Roth K;
    Clin Nephrol; 2012 Jul; 78(1):24-32. PubMed ID: 22732334
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BiOsimilaRs in the management of anaemia secondary to chemotherapy in HaEmatology and Oncology: results of the ORHEO observational study.
    Michallet M; Luporsi E; Soubeyran P; Amar NA; Boulanger V; Carreiro M; Dourthe LM; Labourey JL; Lepille D; Maloisel F; Mouysset JL; Nahon S; Narciso B; Nouyrigat P; Radji R; Sakek N; Albrand H;
    BMC Cancer; 2014 Jul; 14():503. PubMed ID: 25011615
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.